Five Year Results of the First US FDA-Approved Hip Resurfacing Device
A prospective, multi-center postmarket approval study has been ongoing since May 2006 to assess safety and efficacy of the first US FDA approved hip resurfacing implant. 265 patients have been enrolled at five study sites. The average age of the patients is 51.3 years. There have been 7 revisions (2.4%) in the cohort to date. K-M survival curves for the cohort are 97.6% at 5 years. There is a trend toward a gender difference in implant survivorship, with 98.6% of men and 94.7% of women free from revision. Metal ion analysis revealed median cobalt and chromium levels of 1.5 ppb and 1.7 ppb at 1 year. In this prospective US study, the Birmingham Hip Resurfacing implant is demonstrating results comparable to those in the literature.
Back
Essential cookies keep the site secure and functional. You can choose whether to allow non-essential cookies below.
Necessary
Required for security, navigation, and core site functionality. These always stay on.
Remember choices such as display preferences to improve your experience on return visits.
Help us understand how visitors use the site so we can improve performance and usability.
Support campaign tracking and embedded third-party tools that help us reach the right audience.
